Beste apotheek van Nederland

Burke J P, Jacobson D J, McGree M E et al. Diabetes and sexual
dysfunction: results from the Olmsted County study of urinary
symptoms and health status among men. Br J Urol
2007;177(4):1438-1442.
Burke M A, McEvoy J P, Ritchie J C. A pilot study of a
structured interview addressing sexual function in men with
schizophrenia. Biol Psychiatry 1994;35(1):32-35.
Burnett A L. Nitric oxide-based therapy for erectile disorders.
Drug Discovery Today: Therapeutic Strategies 2005;2(1):25-30.
Burnett A L. Pathophysiology of priapism: Dysregulatory
erection physiology thesis. Br J Urol 2003;170(1):26-34.
Burnett A L. Rationale for cavernous nerve restorative therapy
to preserve erectile function after radical prostatectomy. Urology
2003;61(3):491-497.
Burnett A L. Role of nitric oxide in the physiology of erection.
Biol Reprod 1995;52(3):485-489.
Burnett A L. Salvage Techniques for Phosphodiesterase 5
Inhibitor Therapy: Purposeful but How Much?. Eur Urol
2006;50(1):29-30.
Burnett A L, Lue T F. Neuromodulatory therapy to improve
erectile function recovery outcomes after pelvic surgery.
[Review] [50 refs]. Br J Urol 2006;176(3):882-887.
Burnett A L, Allen R P, Davis Wright D C et al. Near infrared
spectrophotometry for the diagnosis of vasculogenic erectile
dysfunction. Int J Impot Res 2000;12(5):247-254.
Burnett A L, Bivalacqua T J, Champion H C et al. Feasibility of
the use of phosphodiesterase type 5 inhibitors in a
pharmacologic prevention program for recurrent priapism. Br J
Sex Med 2006;3(6):1077-1084.
Burnett A L, Bivalacqua T J, Champion H C et al. Long-term
oral phosphodiesterase 5 inhibitor therapy alleviates recurrent
priapism. Urology 2006;67(5):1043-1048.
Burnett A L, Musicki B, Bivalacqua T J. Molecular science of
priapism. Current Sexual Health Reports 2007;4(1):9-14.
Burnett A L, Musicki B, Jin L et al. Nitric oxide/redox-based
signalling as a therapeutic target for penile disorders. Expert
Opin Ther Targets 2006;10(3):445-457.
Burnstock G. Purinergic signalling: Therapeutic potential.
Anales de la Real Academia Nacional de Farmacia
2005;71(2):283-319.
Burnstock G. Potential therapeutic targets in the rapidly
expanding field of purinergic signalling. Clin Med (Northfield
Il) 2002;2(1):45-53.
Burnstock G. Pathophysiology and therapeutic potential of
purinergic signaling. Pharmacol Rev 2006;58(1):58-86.
Butler R N, Lewis M I, Hoffman E et al. Love and sex
after 60: how to evaluate and treat the impotent older
man. A roundtable discussion: Part 2.[see comment].
Geriatrics 1994;49(10):27-32.
Buvat J, Bou Jaoude G. Significance of hypogonadism
in erectile dysfunction. World J Urol 2006;24(6):657­
667.
Buyyounouski M K, Horwitz E M, Price R A et al.
Intensity-modulated radiotherapy with MRI simulation
to reduce doses received by erectile tissue during
prostate cancer treatment. Int J Radiat Oncol Biol
Phys 2004;58(3):743-749.
Buzelin J M, Fonteyne E, Kontturi M et al.
Comparison of tamsulosin with alfuzosin in the
treatment of patients with lower urinary tract
symptoms suggestive of bladder outlet obstruction
(symptomatic benign prostatic hyperplasia). Br J Urol
1997;80(4):597-605.
Byrne R R, Henry G D, Rao D S et al. Vascular
endothelial growth factor restores corporeal smooth
muscle function in vitro. Br J Urol 2001;165(4):1310­
1315.
Caballero J, Nahata M C. Atomoxetine Hydrochloride
for the Treatment of Attention-Deficit/ Hyperactivity
Disorder. Clin Ther 2003;25(12):3065-3083.
Cade Brian W. Unpredictability and change: A
holographic metaphor. Weeks, Gerald R (Ed)
1991;(1991):325
Cakan M, Yalcinkaya F, Demirel F et al. Is dorsale
penile vein ligation (dpvl) still a treatment option in
veno-occlusive dysfunction?. International Urology &
Nephrology 2004;36(3):381-387.
Calil I, Tineli R A, Vicente W V D A et al. The
concept of crosstalk and its implications for
cardiovascular function and disease. Arq Bras Cardiol
2007;88(1):e25-e30.
Cambio A J, Evans C P. Outcomes and quality of life
issues in the pharmacological management of benign
prostatic hyperplasia (BPH). Therapeutics & Clinical
Risk Management 2007;3(1):181-196.
Campbell B C, Prossinger H, Mbzivo M. Timing of
pubertal maturation and the onset of sexual behavior
among Zimbabwe school boys. Arch Sex Behav
2005;34(5):505-516.
Campbell H E. Clinical monograph for drug formulary
review: erectile dysfunction agents. [Review] [64
refs]. Journal of Managed Care Pharmacy
2005;11(2):151-171.
D-16